Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 29;39(12):224.
doi: 10.1007/s12032-022-01819-4.

Does immunotherapy change the treatment paradigm in metastatic gastric cancer?

Silvia Camera  1 , Nicole Liscia  2 , Silvia Foti  2 , Lavinia Barbieri  3 , Andrea Cossu  3 , Francesco Puccetti  3 , Ugo Elmore  3 , Riccardo Rosati  3 , Mario Scartozzi  4 , Elena Mazza  2 , Stefano Cascinu  2
Affiliations
Review

Does immunotherapy change the treatment paradigm in metastatic gastric cancer?

Silvia Camera et al. Med Oncol. .

Abstract

Gastric cancer represents one of the leading causes of cancer-related death worldwide. Even if the last decade has witnessed an improvement in surgical and systemic treatments, with an increase of overall life expectancy, survival rates still remain unsatisfactory, especially for patients with metastatic disease. Systemic therapies represent the gold standard in the management of stage IV gastric cancer. In this scenario, the availability of effective second and third lines has represented for a long time the only hope to offer an overall survival improvement to these patients. Recently, the advent of immune checkpoint inhibitors has involved also gastric cancer with encouraging efficacy data in the metastatic setting, becoming integral part of the management of selected patients.

Keywords: Clinical practice; Immunotherapy; Metastatic gastric cancer; Systemic treatment.

PubMed Disclaimer

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - DOI - PubMed
    1. SEER Cancer statistics: survival by stage in stomach cancer. Available from: https://seer.cancer.gov/statfacts/html/stomach.html . Accessed 6 June 2022.
    1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64. - DOI - PubMed
    1. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;29(8):CD004064.
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. - DOI - PubMed

Substances

LinkOut - more resources